N Arvind Dasari

27PUBLICATIONS
169CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Neurology and neuromuscular diseasesOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Jan 12, 2026
Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602).

Jonathan R Strosberg, Tyler Zemla, Susan Geyer

|Oct 20, 2025
Are We There Yet? The Telltale Trail of ctDNA in Rectal Cancer.

Alisha H Bent, Arvind Dasari, J Joshua Smith

|Jul 16, 2025
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT.

Andrew J Pellatt, Alisha Bent, Nicholas Hornstein

|May 09, 2025
Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.

Kimberly Perez, Jaydira Del Rivero, Erin B Kennedy

|Mar 31, 2025
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2.

Cathy Eng, Arvind Dasari, Sara Lonardi

|Mar 06, 2025
Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group.

Lakshmi Rajdev, Gentry G King, Christopher H Lieu

Pageof 5

Frequent Collaborators

8 joint publications

Scott Kopetz

7 joint publications

Michael Overman

7 joint publications

Kanwal Raghav

6 joint publications

Van Morris